Hi‑Sen Pharmaceutical

Explore the latest insights on Hi‑Sen Pharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hi‑Sen Pharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal
CompanyDeals

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that it has entered into a collaboration agreement with a partner for the Japan rights to its denosumab injection 60 mg (BA6101),…

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now